Meeting

The National Biodefense Science Board (NBSB) held its inaugural meeting on December 17-18, 2008. Secretary Leavitt welcomed the members of the Board. The Board members were briefed on the Department of Health and Human Services activities related to preventing, preparing for, and responding to adverse health effects of public health emergencies resulting from chemical, biological, nuclear, and radiological events, whether naturally occurring, accidental, or deliberate. At the conclusion of the meeting the Board established four working groups (Pandemic Influenza Working Group, Disaster Medicine Working Group, Markets and Sustainability Working Group, and the U.S. Medical Countermeasure Research and Development Processes for Chemical, Biological, Radiological and Nuclear Agents Working Group).

Meeting Summary:
NBSB – December 2008

Date:
December 17 and 18, 2007

Time:
9:00 a.m. – 5:00 p.m.

Location:
Ronald Reagan Building and International Trade Center
Atrium Ballroom
1300 Pennsylvania Avenue, NW
Washington, DC 20004

Notice:
Federal Register Notice

Agenda
Meeting Agenda

Public Participation
Meetings of the NBSB are open to the public.

December 17, 2007
Session #1: Introduction: The National Biodefense Science Board

9:00 a.m. – 9:15 a.m.	Swearing-In and Introduction Michael O. Leavitt, Secretary of Health and Human Services, U.S. Department of Health and Human Services
9:15 a.m. – 9:30 a.m.	Remarks Robert P. Kadlec, M.D., Special Assistant to the President for HomelandSecurity and Senior Director for Biological Defense Policy
9:30 a.m. – 10:00 a.m.	Challenges and Opportunities in Biodefense RADM W. Craig Vanderwagen, M.D., Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services Andrew von Eschenbach, M.D., Commissioner, Food and Drug Administration, U.S. Department of Health and Human Services Julie Gerberding, M.D., M.P.H., Director, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services
10:00 a.m. – 10:15 a.m.	Chair's Remarks and Agenda Overview
10:15 a.m. – 11:00 a.m.	Introduction of NBSB Members NBSB Voting Members
11:00 a.m. – 11:15 a.m.	Break
11:15 a.m. – 11:30 a.m.	NBSB Structure and Operations CAPT Leigh Sawyer, D.V.M., M.P.H., Executive Director, National Biodefense Science Board, U.S. Department of Health and Human Services
11:30 a.m. – 12:15 p.m.	Introduction of NBSB Ex Officio Members NBSB Ex Officio members

12:15 p.m. – 1:30 p.m.	Lunch Break

Session #2: U.S. Government Policies on Preparedness and Response

1:30 p.m. – 1:45 p.m.	Biodefense Update: From Policy to Practice Brian Kamoie, M.P.H., J.D., Deputy Assistant Secretary for Preparedness and Response and Director, Office of Policy, Strategic Planning & Communications, U.S. Department of Health and Human Services
1:45 p.m. – 2:00 p.m.	Overview of the U.S. Government Preparedness and Response Activities for National Incidences VADM Harvey Johnson (U.S. Coast Guard retired), Deputy Administrator, Federal Emergency Management Agency, U.S. Department of Homeland Security
2:00 p.m. – 2:15 p.m.	Overview of the Department of Health and Human Services Preparedness and Response Activities for Public Health and Medical Emergencies Kevin Yeskey, M.D., Director, Office of Preparedness and Emergency Operations, Department of Health and Human Services, U.S. Department of Health and Human Services

Session #3: Issues and Topics for NBSB Consideration (Part I)

2:15 p.m. – 2:45 p.m.	General Discussion of Proposed Topics and Other Issues NBSB Members and Ex Officio Members
2:45 p.m. – 3:00 p.m.	Break
3:00 p.m. – 4:00 p.m.	Introduction and Discussion of Proposed Topics Evaluate Research and Development Components of the HHS Influenza Preparedness Strategy Robin Robinson, Ph.D., Deputy Director, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services Supporting Medical Countermeasure Development Through Innovation Michael Callahan M.D., D.T.M.&H. (U.K.), M.S.P.H., Program Manager, Accelerated Manufacture of Pharmaceuticals, Defense Sciences Office, The Defense Advanced Research Projects Agency, Department of Defense Addressing Gaps in the Medical Countermeasures Marketplace Richard J. Hatchett, M.D., Associate Director for Radiation Countermeasures Research and Emergency Preparedness, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services Modeling and Metrics to Inform Medical Consequence Assessment Peter Highnam, Ph.D., Senior Advisor, Modeling and Information Technology, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services Special and at–Risk Populations – Considerations for Medical Countermeasure Research, Development, and Deployment Plans Dan Dodgen, Ph.D., Director, Office of At Risk Individuals, Behavioral Health, and Human Services Coordination, U.S. Department of Health and Human Services
4:00 p.m. – 4:45 p.m.	General Discussion and Questions from the Board Session #3 Speakers
4:45 p.m. – 5:00 p.m.	Daily Wrap Up and Adjournment

December 18, 2007
Session #4: The HHS Public Health Emergency Medical Countermeasure Enterprise

9:00 a.m. – 9:15 a.m.	Overview of the Public Health Emergency Medical Countermeasure Enterprise Gerald W. Parker, D.V.M., Ph.D., M.S., Principal Deputy Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services
9:15 a.m. – 9:30 a.m.	Research and Development Michael G Kurilla, M.D., Ph.D.., Director, Office of BioDefense Research Affairs and Associate Director for BioDefense Product Development, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services
9:30 a.m. – 9:45 a.m.	Advanced Development and Acquisition Programs Carol Linden, Ph.D., Acting Director and Deputy Director, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services
9:45 a.m. – 10:00 a.m.	Approval and Licensure of Medical Countermeasures RADM Boris D. Lushniak, M.D., M.P.H., Assistant Commissioner, Office of Counterterrorism & Emerging Threats, U.S. Food and Drug Administration, U.S. Department of Health and Human Services and CDR Carmen Maher, Policy Analyst, Office of Counterterrorism & Emerging Threats, U.S. Food & Drug Administration, U.S. Department of Health and Human Services
10:00 a.m. – 10:15 a.m.	Public Health Preparedness, Stockpiling and Deployment Richard E. Besser, M.D., Director, Coordinating Office for Terrorism Preparedness and Emergency Response, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services
10:15 a.m. – 10:45 a.m.	General Discussion and Questions from the Board Session #4 Speakers
10:45 a.m. – 11:00 a.m.	Break

Session #5: The HHS Pandemic Influenza Program

11:00 a.m. – 11:20 a.m.	Overview of the Department of Health and Human Services Pandemic Influenza Plan Bruce Gellin, M.D., M.P.H., Director, National Vaccine Program Office, U.S.Department of Health and Human Services
11:20 a.m. – 11:40 a.m.	Pandemic Preparedness and Response ActivitiesRobin Robinson, Ph.D., Deputy Director, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services
11:40 a.m. – 12:00 p.m.	General Discussion and Questions from the Board Session #5 Speakers
12:00 p.m. – 1:30 p.m.	Lunch Break

Session #6: Issues and Topics for NBSB Consideration (Part II)

1:30 p.m. – 2:30 p.m.	Roundtable Discussion of Proposed Topics Evaluate Research and Development Components of the HHS Influenza Preparedness Strategy Robin Robinson, Ph.D., Deputy Director, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services Supporting Medical Countermeasure Development Through Innovation Michael Callahan M.D., D.T.M.&H. (U.K.), M.S.P.H., Program Manager, Accelerated Manufacture of Pharmaceuticals, Defense Sciences Office, The Defense Advanced Research Projects Agency, Department of Defense Addressing Gaps in the Medical Countermeasures Marketplace Richard J. Hatchett, M.D., Associate Director for Radiation Countermeasures Research and Emergency Preparedness, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services Modeling and Metrics to Inform Medical Consequence Assessment Peter Highnam, Ph.D., Senior Advisor, Modeling and Information Technology, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services Special and at–Risk Populations – Considerations for Medical Countermeasure Research, Development, and Deployment Plans Dan Dodgen, Ph.D., Director, Office of At Risk Individuals, Behavioral Health, and Human Services Coordination, U.S. Department of Health and Human Services
2:30 p.m. – 3:30 p.m.	Discussion and Consideration of Proposed Topics and Other Issues NBSB Members and Ex Officio Members
3:30 p.m. – 3:45 p.m.	Break
3:45 p.m. – 4:15 p.m.	Public Comment
4:15 p.m. – 4:50 p.m.	NBSB Actions and Next Steps NBSB Members
4:50 p.m. - 5:00 p.m.	Closing Remarks and Adjournment